Diabetes, Metabolic Syndrome and Cardiovascular Disease

Description: There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world.

To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer’s disease.

As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed.

This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Contents:
1. Overview
   1.1 Statement of Report
   1.2 About this Report
   1.3 Scope of the Report
   1.4 Methodology
   1.5 Executive Summary

2. Introduction
   2.1 Demographics of Diabetes
      2.1.1 Worldwide Diabetes
      2.1.2 U.S. Diabetes
   2.2 Economics of Diabetes
      2.2.1 Worldwide Costs of Diabetes
      2.2.2 Costs of Diabetes in the U.S.

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes
   3.1 Pre-Diabetes Syndrome
   3.2 Metabolic Syndrome
      3.2.1 Prevalence of Metabolic Syndrome
      3.2.2 Management of Metabolic Syndrome
      3.2.3 The Outlook for Metabolic Syndrome
      3.2.4 The Debate Regarding Metabolic Syndrome
   3.3 Diabetes and Inflammation
   3.4 Diagnosis of Diabetes Mellitus
   3.5 Progression of Diabetes
   3.6 Risk Factors and Diabetes
      3.6.1 Obesity
      3.6.2 Stress-Induced Hyperglycemia
   3.7 Complications and Co-Morbidities in Type 2 Diabetes
      3.7.1 Preventing Complications and Co-Morbidities in Diabetes
3.7.2 Hypoglycemia Resulting from Treatment
3.8 Cardiovascular Disease (CVD)
3.8.1 CVD Facts
3.8.2 Cardiac Care Therapeutics
3.8.2.1 Anti-Hypertensive Drugs
3.8.2.2 Cholesterol Management Drugs
3.8.2.3 Anticoagulants
3.8.3 CVD Diagnostics

4. Pharmaceutical Industry and the Anti-Diabetes Market
4.1 The Worldwide Pharmaceutical Industry
4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
4.1.2 Global Pharmaceutical Market
4.2 Total Diabetes Drug Market Size and Growth
4.2.1 Sales Forecast for the Global Anti-diabetes Drug Market
4.3 Diabetic Medications Overview
4.3.1 Recent Trends in Diabetic Drug Usage
4.3.2 Market Influence Factors

5. Non-Insulin Anti-Diabetes Products
5.1 Anti-Diabetic Drug Therapy Overview
5.1.1 Sulfonylureas
5.1.2 Meglitinides
5.1.3 Biguanides
5.1.4 Thiazolidinediones (TZDs)
5.1.5 a-Glucosidase Inhibitors
5.1.6 Amylin Analog
5.1.7 Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics
5.1.7.1 Byetta (Exenatide)
5.1.7.2 Bydureon (Exenatide LAR)
5.1.7.3 Victoza (Liraglutide)
5.1.7.4 Tanzeum (Albiglutide)
5.1.7.5 Trulicity (Dulaglutide)
5.1.8 DPP-IV Inhibitors
5.1.8.1 Januvia (Sitagliptin)
5.1.8.2 Onglyza (Saxagliptin)
5.1.8.3 Tradjenta (Linagliptin)
5.1.8.4 Galvus (Vildagliptin)
5.1.8.5 Nesina (Alogliptin)
5.1.9 SGLT-2 Inhibitors
5.1.9.1 Invokana (Canagliflozin)
5.1.9.2 Farxiga (Dapagliflozin)
5.1.9.3 Jardiance (Empagliflozin)
5.1.9.4 Suglat (Ipragliflozin)
5.1.9.5 Lusefi (Luseogliflozin)
5.1.10 Fixed Dose Combination Therapies on the Market
5.1.10.1 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
5.1.11 Comparisons of the Anti-Diabetes Drugs
5.2 Market Drivers and Trends
5.2.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
5.2.2 Latest Additions to the U.S. Non-Insulin Diabetes Drug Market
5.3 Non-Insulin Anti-Diabetes Products in the Pipeline
5.3.1 Novel GLP-1 Agonists and Analogs
5.3.2 Novel DPP-IV Inhibitors
5.3.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
5.3.4 Emerging Anti-Diabetes Targets and Drugs in the Pipeline
5.3.4.1 Novel Approaches to Finding New Drug Targets

6. Insulin
6.1 Insulin Markets
6.1.1 Major Players and Market Share
6.1.2 Patent Expirations
6.1.3 Pathway for Insulin Biosimilars
6.1.3.1 Regulatory Avenues for Biosimilar Approval
6.1.3.2 Lantus Biosimilars
6.1.3.2.1 Abasaglar (formerly Abasria) and Basaglar
6.1.3.2.2 Other Biosimilars
6.1.3.3 Key Issues for Insulin Biosimilars
6.1.4 Innovation Strategies
6.2 Insulin Therapeutics
6.2.1 Recommendations for Insulin Initiation and Administration
6.2.2 Short-Acting Insulin
6.2.3 Rapid-Acting Insulin
6.2.3.1 Ultra Fast-Acting Insulins in Development
6.2.4 Intermediate-Acting Insulin
6.2.5 Long-Acting Insulin
6.2.6 Insulin Mixtures
6.3 Pipeline Insulins in Development
6.3.1 Tresiba (Novo Nordisk)
6.3.2 Ryzodeg (Novo Nordisk)
6.3.3 BIOD-531 (Biodel)
6.3.4 Xultophy (Novo Nordisk)
6.3.5 LixiLan (Sanofi)
6.3.6 rHUPH20 and Insulin (Halozyme)
6.3.7 FlAsp (Novo Nordisk)
6.3.8 BIOD-238, BIOD-250, and BIOD-351 (Biodel)
6.3.9 InsuPatch and InsuPad (Insuline Medical)
6.3.10 Smart Insulins
6.4 Non-Invasive Insulin Delivery
6.4.1 Inhaled Insulin
6.4.1.1 Afrezza
6.4.1.2 Dance Pharmaceuticals and Aerogen (Dance-501)
6.4.1.3 A Chronicle of Inhaled Insulins
6.4.2 Oral Insulin
6.4.3 Transdermal Insulin
6.5 Barriers for Non-Injected Insulin
6.6 Patient Potential for Non-Injected Insulin
6.7 Insulin Delivery Devices
6.7.1 Insulin Pens
6.7.2 Injections Aids
6.7.2.1 Automatic Injectors
6.7.2.2 Syringe Magnifiers
6.7.2.3 Injection Ports
6.7.3 Insulin Jet Injectors
6.7.4 Insulin Pumps
6.7.4.1 External Insulin Pumps
6.7.4.2 Animas OneTouch Ping
6.7.4.3 Animas Vibe
6.7.4.4 Accu-Chek® Combo Insulin Pump System (Roche)
6.7.4.5 MiniMed Paradigm Real-Time Revel (Medtronic)
6.7.4.6 MiniMed 530G with Enlite (Medtronic)
6.7.4.7 Insulet Omnipod
6.7.4.8 DANA IIS (Sooil)
6.7.4.9 t:flex (Tandem Diabetes Care)
6.7.4.10 t:slim (Tandem Diabetes Care)
6.7.4.11 Snap (Asante)
6.7.5 Insulin Infusion Sets
6.7.6 Insulin Patch Pumps in Development or Only Available Outside the U.S.
6.7.7 Implantable Insulin Pumps
6.7.8 Insulin Pump Market Share
6.7.9 Drivers of Demand for Pumps
6.8 Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products
7.1 Projections for the Anti-Diabetes Drug Market
7.2 Artificial Pancreas
7.2.1 MiniMed 530G System
7.2.2 Animas® Vibe™ System
7.2.3 Next generation Medtronic Artificial Pancreas Systems (MiniMed 640G)
7.2.4 FDA's Artificial Pancreas Guidance Document
7.3 Insulin-Producing Cells
7.3.1 Gene Therapy
7.3.2 Cell Therapy Companies for Diabetes
7.3.2.1 ViaCyte (formerly Novocell, Inc.)
7.3.2.2 Sernova
7.4 Pancreatic Transplantation
7.4.1 Candidates for Pancreatic Transplantation
7.4.1.1 Pancreatic Organ Transplantation
7.4.1.2 Allo-Islet Transplantation
7.4.1.3 Implantation of Genetically Engineered Cells or Embryonic Stem Cells
7.4.2 ADA Position on Pancreatic Transplantation
7.5 Immune Modulators
7.6 Gastric Bypass Surgery to Treat Type 2 Diabetes
7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
7.7.1 Xenical (Roche)
7.7.2 Qsymia (Vivus)
7.7.3 Belviq (Arena Pharmaceuticals)
7.7.4 Contrave (Orexigen Therapeutics)
7.7.5 Anti-Obesity Drugs in Development
7.8 Other Anti-Diabetic Therapy Drug Candidates
7.8.1 Lipid Abnormalities
7.8.1.1 New Cholesterol Guidelines
7.8.2 High Blood Pressure
7.8.3 Aspirin Therapy
7.8.4 Pre-Mixed Glucagon for Self-Treating Hypoglycemia
7.9 Drugs Used “Off-Label”
7.9.1 Warfarin Sodium
7.10 Insulin and Anti-diabetes Drug Combinations
7.10.1 Xultophy (Novo Nordisk)
7.10.2 LixiLan (Sanofi)

8. Diagnosing Diabetes Using In Vitro Laboratory Tests
8.1 Diagnostic Guidelines
8.2 Diagnosis of Diabetes
8.2.1 Fasting Plasma Glucose (FPG) Test
8.2.2 Glucose Tolerance Test
8.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c)
8.2.4 Fructosamine
8.2.5 Screening Tests for Diabetes-Related Complications
8.3 Glucose Monitoring
8.3.1 Overview of Market Segment
8.3.2 Competitive Strategies
8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix
8.3.3.1 First-Generation Monitors
8.3.3.2 Second-Generation Monitors
8.3.3.3 Third-Generation SMBG Technologies
8.3.3.4 Product Overview
8.3.3.4.1 LifeScan
8.3.3.4.2 Roche Diagnostics
8.3.3.4.3 Bayer HealthCare
8.3.3.4.4 Abbott Diabetes Care
8.3.3.4.5 Other Players
8.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device?
8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development
8.3.6 Future of Non-Invasive Glucose Technology
8.3.7 Lancets and Lancing Devices

9. Market Trends, Challenges and Strategic Options
9.1 Overview
9.2 Diabetes Drug Market Trends
9.2.1 Overview
9.2.2 Emergence of Therapeutics with Improved Administration Characteristics
9.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
9.2.3 Increasing Prevalence of Obesity
9.2.4 Consumer Preference Drives Product Development in Invasive Technology Segment
9.3 Diabetes Mellitus Market Challenges
9.3.1 Overview
9.3.2 Patent Expirations
9.3.3 Market Prospects of Inhalable Insulin
9.4 Strategic Options
9.4.1 Developing Countries are Key Markets for Growth
9.4.2 Consumer-Driven Marketing Campaigns
9.4.3 Strategies for Successful New Product Launches
9.4.4 Collaborations and Strategic Alliances
9.5 FDA Guidelines for Developing Anti-Diabetic Drugs
9.6 Recent Industry Activity

10. Company Profiles
10.1 A. Menarini
10.2 Abbott Laboratories
10.3 Abbvie
10.4 Amgen
10.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
10.6 Animas (part of Johnson & Johnson)
10.7 Asante
10.8 Astellas Pharma, Inc.
10.9 AstraZeneca PLC
10.10 Bayer
10.11 Becton, Dickinson and Company
10.12 Biocon
10.13 Biodel
10.14 BodyMedia
10.15 Boehringer Ingelheim
10.16 Bristol Myers Squibb
10.17 Cellnovo
10.18 CeQur
10.19 ConjuChem
10.20 Daiichi Sankyo
10.21 Dance Biopharm
10.22 Debiotech
10.23 DexCom
10.24 Echo Therapeutics, Inc.
10.25 Eli Lilly
10.26 FIFTY50 Medical, Inc.
10.27 Flamal Technologies
10.28 Generex Biotechnology Corporation
10.29 GlaxoSmithKline PLC
10.30 Halozyme Therapeutics
10.31 Insulet
10.32 Insuline Medical Ltd.
10.33 Intarcia Therapeutics, Inc.
10.34 Janssen Research & Development
10.35 Johnson & Johnson
10.36 Kowa Pharmaceuticals
10.37 Lexicon Pharmaceuticals
10.38 MannKind Corporation
10.39 Medipacs
10.40 Medtronic
10.41 Merck & Company, Inc.
10.42 Mitsubishi Tanabe Pharma Corporation
10.43 Novartis
10.44 Novo Nordisk
Appendix 1: The History of Insulin

Index Of Figures
Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035
Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010
Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010
Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012
Figure 3.1: Maintenance of Normal Blood Sugar Levels
Figure 3.2: Prevalence of Self-Reported Obesity (BMI 30) Among U.S. Adults, 2012
Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010
Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010
Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex in the U.S., 1997-2011
Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age in the U.S., 1997-2011
Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment in the U.S., 1997-2011
Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009
Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009
Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular Disease in the U.S., 2010
Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010
Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010
Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010
Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2007-2012
Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2012-2019
Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2012-2019
Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2014
Figure 5.1: Overview of GLP-1 and Blood Glucose
Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose
Figure 5.3: SGLT-2 Inhibitor Mechanism of Action
Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2014
Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2014
Figure 6.1: Global Sales of Lantus, 2005-2014
Figure 6.2: Insulin Pump Market Share, 2014

Index Of Tables
Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035
Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group), 2013 and 2035
Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
Table 2.5: U.S. Population of Diagnosed Diabetes Aged 20-79 Years, 2013
Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012
Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009
Table 2.9: Healthcare Utilization by Diabetic Patients, 2012
Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic Syndrome Criteria
Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
Table 3.4: Additional Metabolic Criteria for Research
Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
Table 3.7: Prevalence of Complications Among Patients with Diabetes
Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
Table 3.9: Major Causes of End-Stage Renal Disease
Table 3.10: Clinical Recommendations for Adults with Diabetes
Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
Table 3.13: Summary of Cardiovascular Diseases (CVDs)
Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008
Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010
Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016
Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017
Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2014
Table 4.3: Leading Therapy Classes for R&D, 2014
Table 4.4: Leading Disease Indications for R&D, 2014
Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
Table 4.7: World Pharmaceutical Sales Share by Region, 2013
Table 4.8: Leading Ten Therapeutic Classes by Global Sales, 2010-2014
Table 4.9: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2018
Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Pharmarising Market, 2018
Table 4.11: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013
Table 4.12: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2009-2013
Table 4.13: Top Selling Drugs Worldwide by Sales, 2014
Table 4.14: Top Selling Drugs in the U.S. by Sales, 2014
Table 4.15: Top Ten Global Pharmaceutical Companies by Global Sales, 2014
Table 4.16: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
Table 4.17: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
Table 4.18: Anti-Diabetic Therapy Markets, 2014
Table 4.19: Top Ten Branded Anti-Diabetics by Sales Worldwide, 2014
Table 4.20: Top Ten Branded Anti-Diabetics by Monthly Prescriptions Worldwide, 2014
Table 4.21: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy
Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
Table 5.3: Relative Efficacy of Diabetes Drugs
Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations
Table 5.5: Worldwide Non-Insulin Anti-Diabetes Drug Market, 2012-2019
Table 5.6: U.S. Non-Insulin Anti-Diabetes Drug Market, 2012-2019
Table 5.7: Diabetes Drugs Approved for U.S. Market, 2014 and 2015
Table 5.8: GLP-1 Agonist Pipeline: Selected Drugs in Development
Table 5.9: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
Table 5.10: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
Table 5.11: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
Table 5.12: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
Table 5.13: Value Market Shares of Animal, Human and Modern Insulin, 1995-2014
Table 5.14: Worldwide Insulin Market, 2012-2019
Table 5.15: Worldwide Insulin Sales and Market Share by World Region, 2014
Table 5.16: U.S. Insulin Market, 2012-2019
Table 6.1: Key Drivers of the Type 2 Diabetes Insulin Market, 2014
Table 6.2: Worldwide Insulin Sales and Value Market Share by Company, 2014
Table 6.3: U.S. Insulin Sales and Value Market Share by Company, 2014
Table 6.4: Insulins on the U.S. Market
Table 6.5: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
Table 6.6: Pharmacokinetics of Short-Acting Insulins
Table 6.7: Pharmacokinetics of Rapid-Acting Insulins
Table 6.8: Pharmacokinetics of Intermediate-Acting Insulins
Table 6.9: Pharmacokinetics of Long-Acting Insulins
Table 6.10: Pharmacokinetics of Insulin Mixtures
Table 6.11: Pharmacokinetics of Insulin Mixtures
Table 6.12: Comparison of Existing Insulin Delivery Devices
Table 6.13: Insulin Pens
Table 6.14: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
Table 6.15: Injection Aids
Table 6.16: Jet Injectors
Table 6.17: Control Averages by Treatment
Table 6.18: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
Table 6.19: Insulin Pump Manufacturers
Table 6.20: Insulin Infusion Sets
Table 6.21: Comparison of Current External Insulin Pumps on the Market
Table 6.23: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
Table 6.24: Cells of the Pancreas
Table 6.25: Statin Recommendations for Designated Treatment Groups
Table 6.26: Statins Currently Available in the U.S.
Table 6.27: Statin Intensity Chart
Table 6.28: Summary of Non-Statin Cholesterol Lowering Drugs
Table 6.29: Suggested Pharmacological Treatment Agents for Hypertension
Table 6.30: Criteria for the Diagnosis of Diabetes
Table 6.31: Categories of Increased Risk for Diabetes (Pre-Diabetes)
Table 6.32: Normal Glucose Values-Fasting State
Table 6.33: Criteria for Testing for Diabetes in Asymptomatic Adults
Table 6.34: Criteria for Type 2 Diabetes in Asymptomatic Children
Table 6.35: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
Table 6.36: Laboratory Assessment of Diabetic Vascular Disease
Table 6.37: Worldwide Glucose Self-Testing Market Sales (Meters, Strips and Lancets), 2012-2018
Table 6.38: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2012-2018
Table 6.40: Lancet Characteristics
Table 7.1: BRIC Countries, Percentage of GDP Spent on Healthcare, 2013
Table A1.1: Select Archived Press Release Excerpts

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3037907/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Diabetes, Metabolic Syndrome and Cardiovascular Disease
- **Web Address:** [http://www.researchandmarkets.com/reports/3037907/](http://www.researchandmarkets.com/reports/3037907/)
- **Office Code:** SCBR12UA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Description</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 5500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td>☐</td>
<td>USD 11000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 16500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:**
  - Mr ☐
  - Mrs ☐
  - Dr ☐
  - Miss ☐
  - Ms ☐
  - Prof ☐
- **First Name:** ____________________________
- **Last Name:** ____________________________
- **Email Address:** *
- **Job Title:** ____________________________
- **Organisation:** ____________________________
- **Address:** ____________________________
- **City:** ____________________________
- **Postal / Zip Code:** ____________________________
- **Country:** ____________________________
- **Phone Number:** ____________________________
- **Fax Number:** ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World